Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | FAAH | O00519 | 7/20 | 0.62 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.59 |
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456865 | 1.00 | CNR1 (0.68) | CNR1FAAHDNM1CASP2MEN1 | |
| SCHEMBL1456478 | 1.00 | CNR1 (0.68) | CNR1FAAHDNM1CASP2MEN1 | |
| SCHEMBL1695972 | 1.00 | CNR1 (0.68) | CNR1FAAHDNM1CASP2MEN1 | |
| SCHEMBL17125686 | 0.98 | CNR1 (0.69) | CNR1FAAHDNM1CASP2MEN1 | |
| SCHEMBL8847697 | 0.92 | CNR1 (0.67) | CNR1FAAHDNM1CASP2MEN1 | |
| SCHEMBL24415817 | 0.91 | FAAH (0.61) | CNR1FAAHDNM1CASP2MEN1 | |
| SCHEMBL16619882 | 0.91 | CNR1 (0.84) | CNR1MEN1KMT2ALPAR2EPHX2 | |
| SCHEMBL26044981 | 0.91 | CNR1 (0.84) | CNR1MEN1KMT2ALPAR2EPHX2 | |
| SCHEMBL16619880 | 0.91 | CNR1 (0.84) | CNR1MEN1KMT2ALPAR2EPHX2 | |
| SCHEMBL24810920 | 0.89 | CASP2 (0.65) | CNR1FAAHDNM1CASP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-7154004-B2 | Catalytic transamidation and amide metathesis under moderate conditions | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-20040230078-A1 | Catalytic transamidation and amide metathesis under moderate conditions | NATIONAL SCIENCE FOUNDATION | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230078-A1 | Catalytic transamidation and amide metathesis under moderate conditions | NAAA, NIT2, NAT10 | CNR1 1426/4885FAAH 43/4885DNM1 611/4885 |
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | PTGIS, NOS2, PTGIR | CNR1 766/4885FAAH 650/4885DNM1 1270/4885 |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | PTGIS, NOS2, NOS1 | CNR1 1682/4885FAAH 233/4885DNM1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.